Amicus Therapeutics Inc. (NASDAQ:FOLD) shares saw unusually-strong trading volume on Thursday . Approximately 2,301,262 shares changed hands during trading, a decline of 1% from the previous session’s volume of 2,333,937 shares.The stock last traded at $5.94 and had previously closed at $5.68.

A number of research firms have recently weighed in on FOLD. Goldman Sachs Group Inc. began coverage on shares of Amicus Therapeutics in a research report on Wednesday, March 30th. They issued a “neutral” rating and a $10.00 price target for the company. Robert W. Baird began coverage on shares of Amicus Therapeutics in a research report on Wednesday, April 13th. They issued a “neutral” rating and a $9.00 price target for the company. Bank of America Corp. began coverage on shares of Amicus Therapeutics in a research report on Wednesday, May 18th. They issued a “buy” rating and a $10.00 price target for the company. Leerink Swann reiterated an “outperform” rating and issued a $19.00 price target (up from $17.00) on shares of Amicus Therapeutics in a research report on Tuesday, June 14th. Finally, Chardan Capital lifted their price target on shares of Amicus Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, April 12th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Amicus Therapeutics has an average rating of “Buy” and an average target price of $12.88.

The firm has a 50 day moving average price of $6.32 and a 200-day moving average price of $7.15. The company’s market cap is $783.89 million.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.01. Equities analysts expect that Amicus Therapeutics Inc. will post ($1.35) EPS for the current year.

In related news, General Counsel Ellen Rosenberg bought 15,000 shares of Amicus Therapeutics stock in a transaction dated Thursday, June 2nd. The stock was purchased at an average cost of $7.67 per share, with a total value of $115,050.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Several hedge funds and institutional investors recently added to or reduced their stakes in the stock. Columbus Circle Investors increased its position in Amicus Therapeutics by 122.7% in the fourth quarter. Columbus Circle Investors now owns 227,889 shares of the biopharmaceutical company’s stock worth $2,211,000 after buying an additional 125,574 shares in the last quarter. ProShare Advisors LLC increased its position in Amicus Therapeutics by 15.6% in the fourth quarter. ProShare Advisors LLC now owns 117,318 shares of the biopharmaceutical company’s stock valued at $1,138,000 after buying an additional 15,789 shares during the period. Nationwide Fund Advisors increased its position in Amicus Therapeutics by 1.7% in the fourth quarter. Nationwide Fund Advisors now owns 105,597 shares of the biopharmaceutical company’s stock valued at $1,024,000 after buying an additional 1,754 shares during the period. TD Asset Management Inc. increased its position in Amicus Therapeutics by 1.5% in the fourth quarter. TD Asset Management Inc. now owns 178,700 shares of the biopharmaceutical company’s stock valued at $1,733,000 after buying an additional 2,600 shares during the period. Finally, Jennison Associates LLC increased its position in Amicus Therapeutics by 3.3% in the fourth quarter. Jennison Associates LLC now owns 4,123,955 shares of the biopharmaceutical company’s stock valued at $40,002,000 after buying an additional 133,138 shares during the period.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.